Cargando…

A novel, automated, quantification of abnormal lung parenchyma in patients with COVID-19 infection: Initial description of feasibility and association with clinical outcome

OBJECTIVE: Ground-glass opacities are the most frequent radiologic features of COVID-19 patients. We aimed to determine the feasibility of automated lung volume measurements, including ground-glass volumes, on the CT of suspected COVID-19 patients. Our goal was to create an automated and quantitativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Noll, Eric, Soler, Luc, Ohana, Mickael, Ludes, Pierre-Olivier, Pottecher, Julien, Bennett-Guerrero, Elliott, Veillon, Francis, Goichot, Bernard, Schneider, Francis, Meyer, Nicolas, Diemunsch, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664353/
https://www.ncbi.nlm.nih.gov/pubmed/33197638
http://dx.doi.org/10.1016/j.accpm.2020.10.014
_version_ 1783609827861200896
author Noll, Eric
Soler, Luc
Ohana, Mickael
Ludes, Pierre-Olivier
Pottecher, Julien
Bennett-Guerrero, Elliott
Veillon, Francis
Goichot, Bernard
Schneider, Francis
Meyer, Nicolas
Diemunsch, Pierre
author_facet Noll, Eric
Soler, Luc
Ohana, Mickael
Ludes, Pierre-Olivier
Pottecher, Julien
Bennett-Guerrero, Elliott
Veillon, Francis
Goichot, Bernard
Schneider, Francis
Meyer, Nicolas
Diemunsch, Pierre
author_sort Noll, Eric
collection PubMed
description OBJECTIVE: Ground-glass opacities are the most frequent radiologic features of COVID-19 patients. We aimed to determine the feasibility of automated lung volume measurements, including ground-glass volumes, on the CT of suspected COVID-19 patients. Our goal was to create an automated and quantitative measure of ground-glass opacities from lung CT images that could be used clinically for diagnosis, triage and research. DESIGN: Single centre, retrospective, observational study. MEASUREMENTS: Demographic data, respiratory support treatment (synthetised in the maximal respiratory severity score) and CT-images were collected. Volume of abnormal lung parenchyma was measured with conventional semi-automatic software and with a novel automated algorithm based on voxels X-Ray attenuation. We looked for the relationship between the automated and semi-automated evaluations. The association between the ground-glass opacities volume and the maximal respiratory severity score was assessed. MAIN RESULTS: Thirty-seven patients were included in the main outcome analysis. The mean duration of automated and semi-automated volume measurement process were 15 (2) and 93 (41) min, respectively (p = 8.05*10(−8)). The intraclass correlation coefficient between the semi-automated and automated measurement of ground-glass opacities and restricted normally aerated lung were both superior to 0.99. The association between the automated measured lung volume and the maximal clinical severity score was statistically significant for the restricted normally aerated (p = 0.0097, effect-size: −385 mL) volumes and for the ratio of ground-glass opacities/restricted normally aerated volumes (p = 0.027, effect-size: 3.3). CONCLUSION: The feasibility and preliminary validity of automated impaired lung volume measurements in a high-density COVID-19 cluster was confirmed by our results.
format Online
Article
Text
id pubmed-7664353
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-76643532020-11-16 A novel, automated, quantification of abnormal lung parenchyma in patients with COVID-19 infection: Initial description of feasibility and association with clinical outcome Noll, Eric Soler, Luc Ohana, Mickael Ludes, Pierre-Olivier Pottecher, Julien Bennett-Guerrero, Elliott Veillon, Francis Goichot, Bernard Schneider, Francis Meyer, Nicolas Diemunsch, Pierre Anaesth Crit Care Pain Med Original Article OBJECTIVE: Ground-glass opacities are the most frequent radiologic features of COVID-19 patients. We aimed to determine the feasibility of automated lung volume measurements, including ground-glass volumes, on the CT of suspected COVID-19 patients. Our goal was to create an automated and quantitative measure of ground-glass opacities from lung CT images that could be used clinically for diagnosis, triage and research. DESIGN: Single centre, retrospective, observational study. MEASUREMENTS: Demographic data, respiratory support treatment (synthetised in the maximal respiratory severity score) and CT-images were collected. Volume of abnormal lung parenchyma was measured with conventional semi-automatic software and with a novel automated algorithm based on voxels X-Ray attenuation. We looked for the relationship between the automated and semi-automated evaluations. The association between the ground-glass opacities volume and the maximal respiratory severity score was assessed. MAIN RESULTS: Thirty-seven patients were included in the main outcome analysis. The mean duration of automated and semi-automated volume measurement process were 15 (2) and 93 (41) min, respectively (p = 8.05*10(−8)). The intraclass correlation coefficient between the semi-automated and automated measurement of ground-glass opacities and restricted normally aerated lung were both superior to 0.99. The association between the automated measured lung volume and the maximal clinical severity score was statistically significant for the restricted normally aerated (p = 0.0097, effect-size: −385 mL) volumes and for the ratio of ground-glass opacities/restricted normally aerated volumes (p = 0.027, effect-size: 3.3). CONCLUSION: The feasibility and preliminary validity of automated impaired lung volume measurements in a high-density COVID-19 cluster was confirmed by our results. Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. 2021-02 2020-11-13 /pmc/articles/PMC7664353/ /pubmed/33197638 http://dx.doi.org/10.1016/j.accpm.2020.10.014 Text en © 2020 Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Noll, Eric
Soler, Luc
Ohana, Mickael
Ludes, Pierre-Olivier
Pottecher, Julien
Bennett-Guerrero, Elliott
Veillon, Francis
Goichot, Bernard
Schneider, Francis
Meyer, Nicolas
Diemunsch, Pierre
A novel, automated, quantification of abnormal lung parenchyma in patients with COVID-19 infection: Initial description of feasibility and association with clinical outcome
title A novel, automated, quantification of abnormal lung parenchyma in patients with COVID-19 infection: Initial description of feasibility and association with clinical outcome
title_full A novel, automated, quantification of abnormal lung parenchyma in patients with COVID-19 infection: Initial description of feasibility and association with clinical outcome
title_fullStr A novel, automated, quantification of abnormal lung parenchyma in patients with COVID-19 infection: Initial description of feasibility and association with clinical outcome
title_full_unstemmed A novel, automated, quantification of abnormal lung parenchyma in patients with COVID-19 infection: Initial description of feasibility and association with clinical outcome
title_short A novel, automated, quantification of abnormal lung parenchyma in patients with COVID-19 infection: Initial description of feasibility and association with clinical outcome
title_sort novel, automated, quantification of abnormal lung parenchyma in patients with covid-19 infection: initial description of feasibility and association with clinical outcome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664353/
https://www.ncbi.nlm.nih.gov/pubmed/33197638
http://dx.doi.org/10.1016/j.accpm.2020.10.014
work_keys_str_mv AT nolleric anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT solerluc anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT ohanamickael anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT ludespierreolivier anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT pottecherjulien anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT bennettguerreroelliott anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT veillonfrancis anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT goichotbernard anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT schneiderfrancis anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT meyernicolas anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT diemunschpierre anovelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT nolleric novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT solerluc novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT ohanamickael novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT ludespierreolivier novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT pottecherjulien novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT bennettguerreroelliott novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT veillonfrancis novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT goichotbernard novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT schneiderfrancis novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT meyernicolas novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome
AT diemunschpierre novelautomatedquantificationofabnormallungparenchymainpatientswithcovid19infectioninitialdescriptionoffeasibilityandassociationwithclinicaloutcome